{"disease":{"id":"estrogen-receptor-positive-tumor","name":"estrogen receptor positive tumor"},"drugs":{"marketed":[{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic breast cancer in postmenopausal women with one or more estrogen receptors and/or progesterone receptors and a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04601116","title":"The MASTER Study (MAmmary Cancer STatin ER Positive Study)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3360,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT03503799","title":"Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1191,"lead_sponsor_name":"North Eastern German Society of Gynaecological Oncology","has_results":false},{"nct_id":"NCT04086875","title":"A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":332,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT03250676","title":"Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT06474988","title":"Characterization of Biophysical and Mechanical Parameters on Skin of Breast Cancer Patients","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT03644186","title":"To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":true},{"nct_id":"NCT05868226","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT03750396","title":"Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"Gangnam Severance Hospital","has_results":false},{"nct_id":"NCT02997995","title":"Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT02668666","title":"Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Oana Danciu, MD","has_results":true},{"nct_id":"NCT02957968","title":"Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"Virginia Commonwealth University","has_results":true},{"nct_id":"NCT03870399","title":"Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"AC Camargo Cancer Center","has_results":false},{"nct_id":"NCT04602117","title":"ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}